News Related to US Department of Veterans Affairs

Oral Semaglutide Cuts Heavy Drinking; VA Launches Alcoholism Trial

Aug 08, 2026

Oral semaglutide cut heavy drinking and cravings in an 8-week AUD trial. The VA is testing semaglutide in the CRAVE trial enrolling more than 600 veterans.

Alliance, Allarity Launch Lung Cancer Trials as Phase I Sites Consolidate

Jun 25, 2026

Alliance launches Phase III trial for stage I NSCLC immunotherapy; Allarity starts Phase 2 SCLC trial. Phase I NSCLC trial sites consolidate at top U.S. sites, prompting FDA representation concerns.

Allarity Therapeutics Presents Stenoparib Ovarian Cancer Trial at ESMO Congress

Jun 19, 2026

Allarity Therapeutics will present a Trial-in-Progress poster at the ESMO Gynaecological Cancers Congress 2026 on its Phase 2 ovarian cancer trial of stenoparib. The company also dosed first patients in February 2026 in a VA-funded Phase 2 trial of stenoparib plus temozolomide for relapsed small cell lung cancer.

NRx reports positive FDA feedback on preservative-free ketamine filings

Apr 22, 2026

NRx said the FDA issued a positive review letter on its preservative-free ketamine ANDA, requesting only minor administrative changes. The company also received FDA guidance outlining a path to an NDA for NRX-100 using clinical trial data and real-world evidence.

Phase 3 ALS Trial Launches for Pridopidine as AI Identifies Potential Drug Candidates

Apr 03, 2026

A phase 3 clinical trial has launched for pridopidine as a potential ALS treatment, while AI research identified 18 FDA-approved drugs that may extend survival. Separate studies found a promising three-drug combination for sporadic ALS using new cell models.

GLP-1 Drugs Show Promise in Treating Addiction Across Multiple Substances

Apr 01, 2026

A study of over 600,000 patients reveals GLP-1 drugs may reduce addiction across multiple substances, with 50% fewer substance-related deaths and significant reductions in overdoses and hospitalizations. The drugs work by dampening dopamine signaling in brain reward centers. Researchers are exploring broader applications for these medications beyond diabetes and obesity treatment.

Clinical Trials Embrace AI, Real-World Data Integration, and Digital Protocol Transformation

Feb 25, 2026

Industry leaders highlight advances in AI-enabled trial monitoring, real-world data interoperability, and protocol-driven eSource systems, while emphasizing the need for community engagement in diversity efforts and addressing operational risks in rare disease trials.